中药处方治疗COVID-19:聚焦台湾清冠一号(NRICM101)
本文综述中药治疗COVID-19的疗效与机制,重点介绍清冠一号(NRICM101)等方剂。清冠一号于2020年研发,用于病毒性呼吸道感染,推荐治疗轻度和非重症COVID-19,已在台湾临床采用。综述分析10种中药制剂的共同成分与活性成分,认为中药通过抗病毒、抗炎和免疫调节发挥作用。
要点
- 清冠一号(NRICM101)推荐用于治疗轻度和非重症COVID-19感染。
- 中药方剂如清肺排毒汤、连花清瘟胶囊等具有抗病毒、抗炎和免疫调节活性。
- 清冠一号已在台湾被采用于COVID-19的临床治疗。
核心结论
- 中药具有预防和治疗COVID-19的潜力,通过抗病毒、抗炎和免疫调节活性发挥作用。
- 清冠一号(NRICM101)推荐用于治疗轻度和非重症COVID-19感染,并已在台湾临床采用。
研究设计与样本
- 本文为综述,系统分析和总结了中药治疗COVID-19的疗效、益处及机制。
- 分析了10种中药制剂的共同成分和活性成分,以寻找最有前景的物质。
主要发现
- 许多中药成分作用于多个靶点和通路。
- 著名中药方剂包括清肺排毒汤(QFPDT)、连花清瘟胶囊(LHC)、台湾清冠一号(NRICM101)和静思本草饮(JSHD)。
- 清冠一号于2020年研发,用于病毒性呼吸道感染。
关键数值与推荐
- 清冠一号推荐用于治疗非重症和轻度COVID-19感染。
临床怎么用
- 清冠一号已在台湾被采用于COVID-19的临床治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is a strain of coronavirus that causes COVID-19 (coronavirus disease 2019), the respiratory illness responsible for the ongoing COVID-19 pandemic. As at June 2022, increasing numbers of newly diagnosed COVID-19-associated pneumonia cases worldwide have attracted close attention from the international community. The present review analyzes and summarizes the treatment of COVID-19 with traditional Chinese medicine (TCM). A systematic analysis of the efficacies and benefits of TCM for the treatment of COVID-19 was performed, and the mechanisms underlying such treatment are summarized. This analysis of the literature highlights the potential of TCM to prevent and treat COVID-19 via antiviral, anti-inflammatory and immunomodulatory activities, with evidence showing that many TCM components act upon multiple targets and pathways. Famous TCM formulas include Qing-Fei-Pai-Du-Tang (QFPDT), Lianhuaqingwen Capsule (LHC), Taiwan Chingguan Yihau (NRICM101), and Jing Si herbal drink (JSHD). In particular, the botanical preparation NRICM101 was developed in 2020 for use in viral respiratory tract infections and is recommended for treating non-severe and mild COVID-19 infections. NRICM101 has been adopted for use in Taiwan for the clinical treatment of COVID-19. The common components and active ingredients of 10 TCM preparations have been analyzed for the most promising substances. This review aims to provide reliable evidence demonstrating the therapeutic efficacy of TCM substances in support of their further development against novel coronavirus infectious diseases in Taiwan.
引用
- Su YC, Huang GJ, Lin JG, et al. Chinese herbal prescriptions for COVID-19 management: Special reference to Taiwan Chingguan Yihau (NRICM101). Front Pharmacol. 2022. PMID: 36278162. doi:10.3389/fphar.2022.928106
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。